Lunsumio (mosunetuzumab-axgb) vs Jaypirca (pirtobrutinib)
Lunsumio (mosunetuzumab-axgb) vs Jaypirca (pirtobrutinib)
Lunsumio (mosunetuzumab-axgb) is a bispecific antibody designed for the treatment of certain types of B-cell non-Hodgkin lymphoma, which works by redirecting T cells to engage and eliminate targeted B cells. Jaypirca (pirtobrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor used to treat mantle cell lymphoma and other B-cell malignancies, and it works by blocking a specific enzyme that is crucial for the growth and survival of cancer cells. When deciding between these two medications, it is important to consider the specific type of lymphoma, the patient's previous treatments and their efficacy, and the unique side effect profiles of each medication, as well as consulting with a healthcare provider to determine the most appropriate treatment option based on the individual's medical history and condition.
Difference between Lunsumio and Jaypirca
| Metric | Lunsumio (mosunetuzumab-axgb) | Jaypirca (pirtobrutinib) |
|---|---|---|
| Generic name | Mosunetuzumab | Pirtobrutinib |
| Indications | Relapsed or refractory follicular lymphoma | Relapsed or refractory B-cell malignancies |
| Mechanism of action | CD20xCD3 T-cell engaging bispecific antibody | Tyrosine kinase inhibitor |
| Brand names | Lunsumio | Jaypirca |
| Administrative route | IV infusion | Oral |
| Side effects | Cytokine release syndrome, infections, fatigue | Thrombocytopenia, neutropenia, diarrhea |
| Contraindications | None currently known | None currently known |
| Drug class | Bispecific monoclonal antibody | Bruton's tyrosine kinase inhibitor |
| Manufacturer | Genentech, Inc. | Loxo Oncology, Inc. |
Efficacy
Lunsumio (mosunetuzumab-axgb)
Lunsumio (mosunetuzumab-axgb) is a bispecific antibody designed for the treatment of certain types of non-Hodgkin lymphoma (NHL), including follicular lymphoma. It functions by bringing together CD3-positive T-cells and CD20-positive B-cells, leading to the destruction of malignant B-cells. The efficacy of Lunsumio has been evaluated in clinical trials, where it has shown promising results, particularly in patients who have received multiple prior therapies and have limited treatment options.
In a pivotal phase I/II study, Lunsumio demonstrated a high rate of complete responses in patients with relapsed or refractory follicular lymphoma. The treatment was particularly effective in individuals who had not responded to or had relapsed after multiple lines of therapy, including those with resistance to CAR T-cell therapies. The response rates and durability of response observed with Lunsumio suggest that it could offer a valuable new treatment option for patients with difficult-to-treat B-cell lymphomas.
Jaypirca (pirtobrutinib)
Jaypirca (pirtobrutinib) is a highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of mantle cell lymphoma (MCL) and other B-cell malignancies. Pirtobrutinib has been designed to overcome resistance to covalent BTK inhibitors and has shown efficacy in patients who have previously been treated with other BTK inhibitors. The drug has demonstrated promising activity in clinical trials, including those with relapsed or refractory mantle cell lymphoma.
In clinical studies, Jaypirca has exhibited substantial efficacy in patients with B-cell malignancies, including those with mantle cell lymphoma. It has shown a favorable safety profile and the ability to induce responses in patients who have become resistant to or intolerant of previous BTK inhibitor therapies. The data suggest that Jaypirca could provide a new therapeutic option for patients with B-cell lymphomas, particularly for those who have exhausted other treatments.
Regulatory Agency Approvals
Lunsumio
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Jaypirca
-
Food and Drug Administration (FDA), USA
Access Lunsumio or Jaypirca today
If Lunsumio or Jaypirca are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us